Jump to content

Science. Alliances. Partnerships.

A collaborative approach is part of our DNA as it enables us to deliver continuous innovation and increases the ROI for our partners as well as for us. Collaborate with us.

Meet Our Customers

Genedata Customers:
World Leading. Forward Thinking.

Many of the world’s leading biopharmaceuticals, agricultural and industrial biotechs, and academic research institutions collaborate with Genedata. Here is a sampling.

Are You Interested in a Conversation?

We are happy to show you what we already offer and ready to listen to what you are looking for in the future.

Contact Us

Consortia—Solving Real-World Problems.

To help tackle some of the urgent medical research challenges across the globe, Genedata has partnered with research organizations within fields such as toxicology, oncology, and cardiovascular medicine. Here are some of these programs.

BaSysBio (FP6), the Bacillus Systems Biology consortium, represented an integrated systems biology project involving 15 research organizations from nine European countries, studying the global regulation of gene transcription in model bacteria.

BioCop (FP6) was constructed to supply regulators, consumers and industry with long-term solutions to the complex problems associated with chemical contaminant monitoring of foodstuffs.

carcinoGENOMICS (FP6) developed in vitro methods for assessing the carcinogenic potential of compounds.

CVgenes@target (FP7) exploited genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention.

diXa (FP7) established a data management infrastructure for capturing and integrating all (publicly available) toxicogenomic data sets.

EpiFemCare (FP7) was an oncogenomics project to develop a blood based diagnostic test for early detection of breast and ovarian cancer, based on epigenetic markers.

ERANet PathoGenoMics (FP7) used a systems biology approach to investigate the role of small non-coding RNA (sncRNA) in infectious diseases. ERANet provided novel targets for diagnostics and therapy of the five major high-risk gram-positive human microbial pathogens: Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria.

EuRhythDia (FP7) studied chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population.

EXPOsOMICS (FP7) aimed to develop a novel approach to the assessment of exposure to high priority environmental pollutants by characterizing the external and the internal components of the exposome.

FRISYS, the Freiburg Initiative for Systems Biology, focused on modeling and systems analysis of signaling processes in growth and differentiation in human cells and a number of model organisms.

FUNGITECT was a European consortium dedicated to improving the treatment of invasive fungal diseases via individualized anti-fungal drug therapies.

GOBI (General Optimization of Biogas processes) was an interdisciplinary biogas research consortium to improve the overall efficiency of biogas production.

HeCaToS (FP7) aimed at developing integrative in silico tools for predicting human liver and heart toxicity. 

HepatoSys, an interdisciplinary initiative by leading German research centers, aimed to understand the physiology and pathophysiology of the human liver cell using a systems biology approach.

HUMAN (FP7) aimed at the functional validation in animal and cellular models of genetic determinants of diseases and aging processes.

INCA (FP6) investigated the role of chronic viral infections in the development of cancer.

InnoMedPredTox (FP6) aimed at reducing key bottlenecks in the R&D process searching for markers to predict the toxicity of drug candidates.

Kluyver Centre for Genomics and Industrial Fermentation was a joint industry and academic consortium that applied genomics technology to improve industrial fermentation.

MedSys was a multidisciplinary project steered by leading German research centers to identify novel targets for diagnostics, patient risk assessment, and therapy of infectious disease caused by the opportunistic fungal pathogen Candida albicans.

MOD-ENP-TOX (FP7) aimed to develop a novel and generic Modeling Assay Platform (MAP) which can be used as a risk indicator tool to predict the toxicity of metal-based nanoparticles (MeNPs).

NewGeneris (FP6) investigated the role of prenatal and early-life exposure to genotoxic chemicals present in food and the environment in the development of childhood cancer and immune disorders.

NTC (Netherlands Toxicogenomics Centre) used toxigenomics to develop tests that require fewer laboratory animals or cause them less inconvenience, and may eventually replace animal tests completely by in vitro assays using animal or human cells.

PROLIGEN (FP6) consortium studied the regenerative capacity of injured kidneys using information derived from genomics, proteomics, and functional genomics.

SysMAP: Founded and coordinated by the leading specialty chemicals producer Evonik Degussa, the SysMAP consortium exploited novel experimental and computational methods to probe the biological mechanisms underlying industrial fermentation.

Want to Know More About How Genedata Helps Partners Thrive?

Contact Us